Immutep Ltd
Approval AI-extracted
eftilagimod alfa (efti)
soft tissue sarcoma
Date
TBD
Approval decision · Date TBD estimated
What's at stake A final FDA approval decision on eftilagimod alfa (efti) for soft tissue sarcoma is expected Date TBD.
“Primary endpoint met in EFTISARC-NEO Phase II evaluating neoadjuvant efti in soft tissue sarcoma detailed in Proferred Paper oral presentation at ESMO Congress 2025”

Provenance

1 source on file.

Link copied ✓